<a href="https://www.fiercebiotech.com/biotech/lilly-pens-22b-pact-bezos-backed-profluent-work-recombinase-based-gene-editing" hreflang="en">Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing</a>
Eli Lilly has entered a $2.2 billion partnership with Profluent to develop AI-designed recombinases for gene editing, aiming to address significant unmet medical needs. This collaboration follows Lilly's recent trend of strategic acquisitions and partnerships in the genetic medicine space.
Eli Lilly's $2.2 billion partnership with AI-driven startup Profluent highlights a significant investment in AI-designed recombinase technology for gene editing, indicating a strong market opportunity for AI applications in precision medicine and genetic therapies. This collaboration underscores the potential of AI to overcome existing limitations in genetic medicine, suggesting that stakeholders in healthtech and biotech should closely monitor advancements in AI-driven protein design for new therapeutic avenues.